|
Australia – a world class partner in biotechnology
Australia has a diverse biotechnology sector with over 470 core biotech companies covering human therapeutics, agriculture, bioinformatics and convergent technologies such as nano-biotechnology applications. Within human therapeutics Australia has world-class excellence in immunology, stem cells, reproductive medicine, infectious diseases, and oncology, as well as cross-sectoral areas, such as proteomics.
International organisations seeking innovative Australian biotechnology expertise are invited to request an introduction to Australian companies.
Using this service, your organisation can:
- View the list of exhibitors on the BIO 2008 Australian Pavilion.
- Request meetings with Australian companies of interest directly with their key business development managers.
Over 35 innovative Australian leading edge bioscience companies will be at the(booth number 4534) at BIO 2008. AusBiotech is coordinating the Australian Pavilion.
Anadis Limited a global leader in the development and manufacturing of polyclonal antibody products, based on patented colostrum priming and hyper-immunisation technologies. The all-natural dairy-derived platform, has a regulatory classification as GRAS (Generally Regarded as Safe) when administered orally. Leveraging a technology platform that has been carefully developed over a decade, Anadis is addressing a broad range of indications in the infectious diseases, immune mediated diseases and oncology fields. Read more.
APAF is Australia’s premier protein discovery research/service facility working to discover and purify novel biomarkers for human health and agricultural biotech applications. Read more.
Australian Tissue Engineering Centre
A leading provider of innovative tissue engineering solutions is emerging in the heart of Melbourne’s biotech hub. The Australian Tissue Engineering Centre is a collaborative facility that brings world-class stem cell, biomedical engineering and microsurgery research bodies together to drive the delivery of benefits from Australia’s world-class tissue engineering research. Read more.
Chemical Analysis employs the most advanced analytical equipment for meeting project diversity and timelines. We provide assistance in managing products through various stages of the life cycle - Discovery, Preclinical, Clinical and Post-market under tight deadlines. Chemical Analysis is contracted by many leading Pharmaceutical, Biotechnology and Veterinary companies within the Asia-Pacific Region with a high incidence of return business, thus demonstrating the high Quality and Value of service Chemical Analysis provides. Read more.
OVICOLL® is a naturally sourced and highly purified collagen that is a key and distinctive requirement for multiple cosmetic, research and medical applications. Read more.
Diabetes Vaccine Development Centre (DVDC) facilitates the development of immunotherapies to stop the development of type 1 diabetes. It is a joint initiative of the Australian Government’s National Health and Medical Research Council (NHMRC) and the New York based Juvenile Diabetes Research Foundation International (JDRF). Read more.
Epichem provides services in synthetic and medicinal chemistry to the drug discovery and pharmaceutical industries. Epichem has an extensive array of equipment including a full range of parallel synthesis equipment to produce analogue libraries. Its laboratories also have full height fumehoods for large laboratory scale synthesis up to 1kg. Read more.
FABLS is an international network of 430 people with expertise in biological and biomedical sciences, chemistry, physics, optoelectronics, and medical research. Based in Australia, its focus is on the development of precision instrumentation, reagents and software to expand the boundaries in cellular diagnostics and imaging, environmental monitoring and the treatment of disease. Read more.
Fermiscan is commercialising a new diagnostic test for the presence of breast cancer based on X-ray diffraction of scalp hair. Fermiscan’s technology is protected by granted patents in the US, Australia, New Zealand and the EU, with patents pending in other major countries. The test is suitable for women of any age, is safe and its accuracy has been demonstrated in blinded trials. Read more.
GleneaglesCRC is a premier CRO focused on operations in the Asian and Australasian region, specialised in phase 1 to phase 4 clinical trials services. With an unparalleled network of sites and investigators, as well as cutting edge technology and a world-class infrastructure to support your needs, GleneaglesCRC is well positioned to assist you in any stage of your clinical R&D efforts. Local expertise at global standards is what we offer. Read more.
Australia’s Griffith University, Queensland is a regional leader in biotechnology with the Eskitis Institute, Institute for Glycomics and Genomics Research Centre. These centres collaborate with key industry and public sector health partners to deliver research benefits to the community through outcomes such as novel therapies, diagnostics, and analytical services. Read more.
Invetech provides innovative contract development and manufacture for instruments, devices, consumables custom integration and custom automation. For more than 30 years, we have worked with leading companies that provide instrument systems for laboratory and research applications; custom automation and integration for research or production processes Our in-house team of 200+ professionals use systematic ISO 9001, IEC 60601, IEC 61010, QSR compliant development processes and FDA registered manufacturing facilities, to deliver high quality, fast-to-market results. Read more.
Living Cell Technologies (LCT) is developing a cell based therapy, for the treatment of type 1 diabetes. The Company's proprietary cell encapsulation technology allows DiabeCell ® to be implanted without the need for toxic anti-rejection drugs. Read more.
Marinova specialises in the extraction of fucoidans, sulphated polysaccharides found in marine macroalgae. The company has developed a library of fucoidan derivatives, and can isolate patentable fractions as active ingredients for pharmaceutical or medical device products. The company is currently developing fucoidan bioactives for wound healing, cardiovascular and antiviral applications. Fucoidans are a natural alternative to heparin with similar bioactivity profiles. Read more.
Murdoch University is a Western Australian-based research intensive university with strong links to industry. Murdoch currently hosts, or is in partnership with over 50 research centers, building on its strengths in veterinary and biomedical sciences, agricultural biotechnology, environmental technology solutions and hydrometallurgy. Read more.
Nanotechnology Victoria Ltd (NanoVic) has developed a portfolio of bionanotechnology activities with considerable commercial potential, exploiting the advantages offered by nanotechnology for improved drug delivery, medical imaging and diagnostic systems. To facilitate commercialisation of these products, two vehicles have been established - Interstitial NanoSystems (Interstitial NS) and Quintain NanoSystems (Quintain NS). Read more.
Newcastle Innovation enables businesses to benefit from breakthrough research in areas such as health, biotechnology, mining, minerals processing and energy, conducted by the University of Newcastle. Read more.
NewSouth Innovations Pty Limited (NSi) is the technology transfer company of the University of New South Wales, with a business model clearly focused on intellectual property (IP) commercialisation via the protection of IP, the licensing of that technology, and capital raising through the formation of spin-off companies. Read more.
The New South Wales Clinical Trials Business Development Centre (the Centre) has recently been established to facilitate national and international companies, wanting to conduct trials in Australia, to access Sydney and regional NSW clinical trialists with world class expertise and the research excellence and infrastructure to translate discovery into products and services. Read more.
Nucleus Network provides a broad range of expertise on clinical research and product development to the global pharmaceutical, biotechnology and medical device industries. Nucleus Network was conceived by clinicians and researchers to provide a framework for world-class clinical research services for the Australian and international biotech industry. Read more.
Optiscan Pty Ltd
Optiscan Imaging Limited (Optiscan) is an Australian company that has developed and patented miniaturised confocal microscopes, and is a global leader in the development and application of microscopic imaging technologies for the medical market. The Company is listed on the Australian Stock Exchange. Read more.
QRxPharma is a clinical-stage specialty pharmaceutical company with a core focus on the development and commercialisation of pain therapy products. The Company’s lead products comprise a patented combination of existing drugs, with a well defined path to regulatory approval and sales. QRxPharma’s lead drug compound, Q8003IR, is intended to begin Phase III clinical trials in 2007. The Company’s preclinical and clinical pipeline includes other technologies in the fields of neurodegenerative disease and venomics. Read more.
QUT is a top Australian university with global connections, a wide range of studies and applied research. QUT has a strong reputation for solving problems for industry and the community, and developing new products. QUT fosters a research environment that supports large-scale, outcome-based research endeavours through focus on areas of research expertise, and internal and external collaboration. Read more.
Seagull Technology's platform drug delivery device is designed for the non-invasive delivery of drugs by an innovative combination of nanotechnology and ultrasound. In its first application, it will facilitate a safer and more comfortable delivery of drugs to the back of the eye to manage diseases such as age-related macular degeneration. Currently needle injections are required every six to eight weeks to prevent blindness. Needle injection in the eye can result in retinal detachment and infection. Read more.
Selborne Biological Services is a leading supplier of specialized products of animal origin for the biotech, pharmaceutical, veterinary, and diagnostics industries. Selborne has been producing high quality biological products for more than 30 years. Its operations now span three continents, with offices in Australia, Europe, and North America. Selborne's principal manufacturing facilities are located in the rural community of Longford on the northern end of Tasmania, Australia's magnificent island state. Read more.
Southern Cross University has a focus on plant science developing value added products in agricultural and food biotechnology. Key technologies in high throughput genome and transcriptome analysis provide opportunities to develop genotypes with unique traits for food, industrial and bioenergy applications. Read more.
SPS is a Sydney-based biopharmaceutical company set up to develop and commercialise bacteriophage therapy products. Read more.
Stirling Products Limited (Stirling) is an animal healthcare company. Stirling currently has two technology platforms. ProVale™ is a market introduced yeast beta Glucan which boosts the hosts immune system. R-salbutamol is a metabolic modifier that repartitions energy ('more muscle less fat'). Stirling's three market areas of interest are: companion animals – including obesity treatment and general health; treatment for respiratory disorders in horses; and growth agents in livestock. Read more.
Sypharma provides solutions to your contract manufacturing problems. Sypharma is one of the newest contract manufacturers of large and small volume parenterals, haemodialysis concentrates, and veterinary medicines in Australia. We provide aseptic and terminally sterilised injectables, biopharmaceutical formulation and processing, as well as a range of other capabilities, including in house chemistry and microbiology. Our dedicated team of professionals will put the GMP into your process. Read more.
TeleMedCare Pty Ltd was established to commercialise home telecare technologies developed by the Biomedical Systems Laboratory at the University of NSW in Australia. The TeleMedCare Service offers flexibility to health professionals to manage patients in their own home. For the first time, professionals are able to extend their formal standards of care, into the informal settings of the home. Read more.
The University of Queensland’s Institute for Molecular Bioscience, Queensland Brain Institute, Australian Institute for Biotechnology & Nanoengineering and Diamantina Institute for Cancer, Immunology & Metabolic Medicine hold nearly 1,000 researchers, and combine leading facilities with a culture of research excellence and technology transfer. Read more.
UniQuest Pty Limited at The University of Queensland UniQuest is widely recognized as one of Australia’s largest and most successful university commercialization groups. For almost 25 years UniQuest has been managing and commercializing an extensive intellectual property portfolio, including core technologies in vaccine development and diagnostic devices. Read more.
The University of Tasmania is the fourth oldest university in Australia. It is a research-led university, with a high standard of teaching and strong international focus. The School of Chemistry has a strong research focus in separation science, environmental, computational, natural products and synthetic chemistry. Read more.
The School of Pharmacy at the University of Tasmania has considerable expertise in the biotech area and undertakes consultancies and collaborative projects with industry over a diverse range of projects including natural product drug discovery and specialised bio-analytical applications. The University and its partners are actively seeking investors and industry partners for commercialisation of exciting products and technologies. Read more.
The University of Western Australia is recognised internationally as a Centre of Research Excellence. UWA is keen to explore opportunities for collaborative research as well as licensing and other commercialisation of its discoveries with interested biotech and pharmaceutical companies. Read more.
University of Wollongong is developing and commercialising early stage intellectual property in the Life science area. Initial focus is on drug reformulation for cancer treatment, cancer targeting biological, GAS vaccine candidates, real time radiation monitoring devices for Brachytherapy and novel nutraceuticals targeting appetite. Read more.
|